(Q73295932)

English

A Randomized, Blinded Study of Two Doses of Novastan(R) (Brand of Argatroban) Versus Heparin as Adjunctive Therapy to Recombinant Tissue Plasminogen Activator (Accelerated Administration) in Acute Myocardial Infarction: Rationale and Design of the M

scientific article published on 01 January 1998

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10608050%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

A Randomized, Blinded Study of Two Doses of Novastan(R) (Brand of Argatroban) Versus Heparin as Adjunctive Therapy to Recombinant Tissue Plasminogen Activator (Accelerated Administration) in Acute Myocardial Infarction: Rationale and Design of the Myocardial Infarction using Novastan(R) and T-PA (MINT) Study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10608050%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

acute myocardial infarction

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Robert P Giugliano

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10608050%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

author name string

Serebruany VL

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10608050%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Jang IK

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10608050%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Massey TJ

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10608050%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Schwarz Jr RP

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10608050%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

publication date

1 January 1998

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10608050%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Journal of Thrombosis and Thrombolysis

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10608050%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10608050%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10608050%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

49-52

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10608050%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

https://scigraph.springernature.com/pub.10.1023/a:1008872031770

0 references

The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction

1 reference

https://pubmed.ncbi.nlm.nih.gov/10608050

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin

1 reference

https://pubmed.ncbi.nlm.nih.gov/10608050

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl++ +) sulfonyl]-l-arginyl)]-2-piperidinecarboxylic acid

1 reference

https://pubmed.ncbi.nlm.nih.gov/10608050

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/10608050

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators

1 reference

https://pubmed.ncbi.nlm.nih.gov/10608050

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine prepa

1 reference

https://pubmed.ncbi.nlm.nih.gov/10608050

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators

1 reference

https://pubmed.ncbi.nlm.nih.gov/10608050

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator

1 reference

https://pubmed.ncbi.nlm.nih.gov/10608050

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded?

1 reference

https://pubmed.ncbi.nlm.nih.gov/10608050

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/10608050

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/10608050

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction

1 reference

https://pubmed.ncbi.nlm.nih.gov/10608050

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator

1 reference

https://pubmed.ncbi.nlm.nih.gov/10608050

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/10608050

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collabo

1 reference

https://pubmed.ncbi.nlm.nih.gov/10608050

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction

1 reference

https://pubmed.ncbi.nlm.nih.gov/10608050

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS)

1 reference

https://pubmed.ncbi.nlm.nih.gov/10608050

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

TIMI frame count: a quantitative method of assessing coronary artery flow

1 reference

https://pubmed.ncbi.nlm.nih.gov/10608050

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The open-artery theory is alive and well--again

1 reference

https://pubmed.ncbi.nlm.nih.gov/10608050

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

1 reference

https://pubmed.ncbi.nlm.nih.gov/10608050

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The thrombin paradox

1 reference

https://pubmed.ncbi.nlm.nih.gov/10608050

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/10608050

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q73295932&oldid=1899739183"